Relevance of Radiolabeled Steroid Inhalation Studies to Clinical Outcomes

Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung

Volumn 11, Issue , 1998, Pages S-29-S-34

  Leach, Chet L ^a  

^a 3M COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; NORFLURANE; STEROID;

ADULT; AEROSOL; CONFERENCE PAPER; DRUG DISTRIBUTION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; ISOTOPE LABELING; METERED DOSE INHALER; NORMAL HUMAN;

ADOLESCENT; ADULT; ANIMALS; ANTI-INFLAMMATORY AGENTS; BECLOMETHASONE; DRUG DELIVERY SYSTEMS; HUMANS; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; RABBITS; RADIOPHARMACEUTICALS; SODIUM PERTECHNETATE TC 99M; TREATMENT OUTCOME;

EID: 0031831781     PISSN: 08942684     EISSN: None     Source Type: Journal    
DOI: 10.1089/jam.1998.11.Suppl_1.S-29     Document Type: Article

References (11)

1. United Nations Environment Programme (Ozone Secretariat). 1996. Handbook for the International Treaties for the Protection of the Ozone Layer, fourth edition. Kenya.
2. Leach, C. L. 1996. Enhanced drug delivery through reformulating MDIs with HFA propellants—drug deposition and its effect on preclinical and clinical programs. In R. N. Dalby, P. R. Byron, and S. J. Farr, eds. Respiratory Drug Delivery V Proceedings. Interpharm Press, Buffalo Grove, IL 133–144.
3. Few, J. D., M. D. Short, and M. L. Thompson. 1970. Preparation of 99mTc labeled particles for aerosol studies. Radiochem. Radioanal. Lett. 5: 275–277.
4. Kohler, D., W. Fleischer, and H. Matthys. 1988. New method for easy labeling of beta-2 agonists in the metered dose inhaler with Tc 99m. Respiration. 53: 65–73.
5. Newman, S. P., D. Pavia, F. Moren, N. F. Sheahan, and S. W. Clarke. 1981. Deposition of pressurized aerosols in the human respiratory tract. Thorax. 36: 52–55.
6. Leach, C., P. Davidson, J. Heilman, and R. Boudrea. 1995. Clinical results of a new technetium-99 labeling and validation method for the deposition of inhaled beclomethasone [abstract]. Eur. Respir. Rev. 8 (Suppl 19): 82S.
7. Harrison, L., C. Leach, and P. Seale. 1997. Improvement in topical lung vs. systemic availability of beclomethasone dipropionate from an extrafine aerosol formulation [abstract]. Eur. Respir. Rev. 10 (Suppl 25): 349S.
8. Harrison, L., I. Soria, J. Machacek, J. Jacobson, A. Purrington, A. Cline, S. McCarville, J. Grassell, D. Dahl, T. Wells, S. Chang, and W. Holland. 1996. Beclomethasone pharmacokinetics in asthmatics given CFC and CFC-free inhalers [abstract]. Eur. Respir. Rev. 9(Suppl 23): 256S.
9. Gross, G., J. VandenBurgt, D. Donnell, M. Amies, and P. Stampone. 1996. New formulation inhaled steroid achieves equivalent peak flow control with half the daily dose in moderate asthmatics [abstract]. Eur. Respir. Rev. 9(Suppl 23): 255S.
10. Davies, R., J. Simmons, P. Stampone, and D. Donnell. 1996. Equivalent asthma symptom control of 1500 meg beclomethasone dipropionate (BDP) achieved with 800 meg BDP from fine aerosol solution [abstract]. Eur. Respir. Rev. 9(Suppl 23): 254S.
11. Kunkel, G., D. Nowak, P. Kristufek, S. Hader, A. Ostendorf, I. Burnett, and W. Harter. 1996. A multinational study assessing the efficacy and safety of a CFC-free beclomethasone pMDI [abstract]. Eur. Respir. Rev. 9(Suppl 23): 254S.